Compare Icl Group Ltd (ICL) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Illumina, Inc. — how do they compare? Icl Group Ltd trades at $5.45 (market cap $6.94B), while Illumina, Inc. trades at $193.06 (market cap $29.12B). The key difference: Illumina, Inc. is far larger — about 4.2× Icl Group Ltd's market cap, and Icl Group Ltd pays a 3.86% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ICL | ILMN | |
|---|---|---|
Market Cap | $6.94B | $29.12B |
Sector | Basic Materials | Health |
52-Week High | $6.84 | $205.10 |
52-Week Low | $4.80 | $91.00 |
Enterprise Value | $9.58B | $30.48B |
Dividend Yield | 3.86% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
